BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 16556896)

  • 1. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.
    Lovejoy AE; Reynolds TC; Visich JE; Butine MD; Young G; Belvedere MA; Blain RC; Pederson SM; Ishak LM; Nugent DJ
    Blood; 2006 Jul; 108(1):57-62. PubMed ID: 16556896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency.
    Kerlin B; Brand B; Inbal A; Halimeh S; Nugent D; Lundblad M; Tehranchi R
    J Thromb Haemost; 2014 Dec; 12(12):2038-43. PubMed ID: 25263390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results.
    Kerlin BA; Inbal A; Will A; Williams M; Garly ML; Jacobsen L; Kearney SL
    J Thromb Haemost; 2017 Aug; 15(8):1601-1606. PubMed ID: 28581691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers.
    Reynolds TC; Butine MD; Visich JE; Gunewardena KA; MacMahon M; Pederson S; Bishop PD; Morton KM
    J Thromb Haemost; 2005 May; 3(5):922-8. PubMed ID: 15869585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic characterization of recombinant factor XIII (FXIII)-A2 across age groups in patients with FXIII A-subunit congenital deficiency.
    Brand-Staufer B; Carcao M; Kerlin BA; Will A; Williams M; Tornøe CW; Sandberg Lundblad M; Nugent D
    Haemophilia; 2015 May; 21(3):380-385. PubMed ID: 25643920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers: a randomized, placebo-controlled, double-blind, multi-dose study.
    Visich JE; Zuckerman LA; Butine MD; Gunewardena KA; Wild R; Morton KM; Reynolds TC
    Thromb Haemost; 2005 Oct; 94(4):802-7. PubMed ID: 16270634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency.
    Carcao M; Altisent C; Castaman G; Fukutake K; Kerlin BA; Kessler C; Lassila R; Nugent D; Oldenburg J; Garly ML; Rosholm A; Inbal A
    Thromb Haemost; 2018 Mar; 118(3):451-460. PubMed ID: 29448295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of recombinant factor XIII in young children with congenital FXIII deficiency and comparison with older patients.
    Williams M; Will A; Stenmo C; Rosholm A; Tehranchi R
    Haemophilia; 2014 Jan; 20(1):99-105. PubMed ID: 23834599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of F13A1 gene mutations in 73 patients treated with recombinant FXIII-A
    Ivaškevičius V; Biswas A; Garly ML; Oldenburg J
    Haemophilia; 2017 May; 23(3):e194-e203. PubMed ID: 28520207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes.
    Carcao M; Fukutake K; Inbal A; Kerlin B; Lassila R; Oldenburg J; Garly ML; Nugent D
    Semin Thromb Hemost; 2017 Feb; 43(1):59-68. PubMed ID: 27556350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reciprocal stabilization of coagulation factor XIII-A and -B subunits is a determinant of plasma FXIII concentration.
    Byrnes JR; Lee T; Sharaby S; Campbell RA; Dobson DA; Holle LA; Luo M; Kangro K; Homeister JW; Aleman MM; Luyendyk JP; Kerlin BA; Dumond JB; Wolberg AS
    Blood; 2024 Feb; 143(5):444-455. PubMed ID: 37883802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential clot stabilising effects of rFVIIa and rFXIII-A2 in whole blood from thrombocytopenic patients and healthy volunteers.
    Johansson PI; Jacobsen N; Viuff D; Olsen EH; Rojkjaer R; Andersen S; Petersen LC; Kjalke M
    Br J Haematol; 2008 Nov; 143(4):559-69. PubMed ID: 18950467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement.
    Pitkänen HH; Jouppila A; Lemponen M; Ilmakunnas M; Ahonen J; Lassila R
    Thromb Res; 2017 Jan; 149():56-61. PubMed ID: 27902939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency.
    Inbal A; Oldenburg J; Carcao M; Rosholm A; Tehranchi R; Nugent D
    Blood; 2012 May; 119(22):5111-7. PubMed ID: 22451421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alloantibodies against the B subunit of plasma factor XIII developed in its congenital deficiency.
    Wada H; Souri M; Matsumoto R; Sugihara T; Ichinose A
    Thromb Haemost; 2013 Apr; 109(4):661-8. PubMed ID: 23407795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary report.
    Levy JH; Gill R; Nussmeier NA; Olsen PS; Andersen HF; Booth FV; Jespersen CM
    Thromb Haemost; 2009 Oct; 102(4):765-71. PubMed ID: 19806264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency.
    Cojutti PG; Zanon E; Pasca S; Pea F;
    Clin Pharmacokinet; 2022 Apr; 61(4):505-513. PubMed ID: 34718987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of recombinant factor XIII-A
    Poulsen LH; Kerlin BA; Castaman G; Molinari AC; Menegatti M; Nugent D; Dey S; Garly ML; Carcao M
    Res Pract Thromb Haemost; 2022 Feb; 6(2):e12628. PubMed ID: 35243202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
    Nugent DJ; Ashley C; García-Talavera J; Lo LC; Mehdi AS; Mangione A
    Haemophilia; 2015 Jan; 21(1):95-101. PubMed ID: 25458735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
    Ashley C; Chang E; Davis J; Mangione A; Frame V; Nugent DJ
    Haemophilia; 2015 Jan; 21(1):102-8. PubMed ID: 25377187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.